Jaypirca

Pirtobrutinib, the active ingredient in Jaypirca, is a Bruton tyrosine kinase (BTK) inhibitor presented as a tablet for oral use. It treats relapsed or refractory mantle cell lymphoma and other B‑cell malignancies in adult patients.

GNH USA supplies Jaypirca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Jaypirca targets B‑cell receptor signaling pathways and is indicated for specific hematologic cancers.

Mantle cell lymphoma: provides a treatment option for relapsed or refractory disease. Chronic lymphocytic leukemia: offers therapy for patients whose disease has progressed after prior treatment. Small lymphocytic lymphoma: used in relapsed or refractory cases where other options have failed.

Adverse reactions may occur with Jaypirca treatment.

Common Side Effects: - Diarrhea - Nausea - Fatigue - Rash

Serious or Rare Side Effects: - Hemorrhage - Infections - Severe skin reactions

Patients receiving Jaypirca should be monitored for safety concerns. - Blood counts: monitor complete blood count regularly to detect cytopenias. - Bleeding risk: assess for signs of bleeding, especially if concomitant anticoagulants are used. - Liver function: evaluate hepatic enzymes before and during therapy. - Drug interactions: review all concomitant medications for potential BTK inhibitor interactions. - Severe hepatic impairment: avoid use in patients with marked liver dysfunction. - Store at below 25°C: keep in the original pack, protect from moisture.

Jaypirca can interact with several drug classes.

Major Interactions (Avoid): - Anticoagulants: increased risk of bleeding. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise pirtobrutinib exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce drug effectiveness.

Moderate Interactions (Monitor Closely): - Antiplatelet agents: monitor for additive bleeding. - CYP2C9 substrates: observe for altered plasma levels. - Live vaccines: consider timing to avoid reduced vaccine efficacy.